CPT® Code 90377

Rabies immune globulin (RIg-HT S/D) is a specialized immunizing agent designed to provide immediate, short-term immunity against the rabies virus. This preparation consists of a concentrated solution of antibodies derived from pooled human plasma collected from donors who have been sensitized with the rabies vaccine. Unlike active immunization, where the body’s immune system is stimulated to produce its own antibodies, the administration of rabies immune globulin offers passive protection. This means that the antibodies present in the immune globulin circulate in the recipient's body, providing immediate defense against the rabies virus without requiring the recipient's immune system to respond. The manufacturing process of RIg-HT S/D includes critical safety measures to ensure the product is free from viral contaminants. Initially, the plasma undergoes solvent/detergent treatment, utilizing a mixture such as tri-(n-butyl) phosphate (TnBP) and Octynoxol 9. This step is essential for inactivating enveloped viruses that may be transmitted through human blood, including HIV and hepatitis B and C. Following this, the product is subjected to heat treatment through pasteurization, which further inactivates any remaining viruses. Some formulations may also incorporate a third step of nanofiltration, which effectively removes additional viral particles based on size. RIg-HT S/D is specifically indicated for administration after exposure to rabies, such as following a bite from a rabid or potentially rabid animal. It is crucial that this immune globulin is administered either intramuscularly or subcutaneously, and it is typically given in conjunction with the rabies vaccine to ensure comprehensive protection. It is important to note that the CPT® Code 90377 specifically reports the rabies immune globulin product itself and does not encompass the administration of the immune globulin or the rabies vaccine.